Premium
Leishmanicidal and trypanocidal activity of extracts and secondary metabolites from basidiomycetes
Author(s) -
Inchausti Alba,
Yaluff Gloria,
Rojas de Arias Antonieta,
Torres Susana,
Ferreira Maria Elena,
Nakayama Hector,
Schinini Alicia,
Lorenzen Kirsten,
Anke Timm,
Fournet Alain
Publication year - 1997
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/(sici)1099-1573(199705)11:3<193::aid-ptr68>3.0.co;2-r
Subject(s) - mycelium , trypanosoma cruzi , biology , microbiology and biotechnology , kinetoplastida , trypanosoma , parasite hosting , botany , virology , world wide web , computer science
Abstract Seventeen extracts and seven secondary metabolites isolated from basidiomycetes were tested in medium culture against promastigote forms of Leishmania spp. and bloodstream forms of Trypanosoma cruzi . Extracts from the culture filtrate or mycelium were generally inactive against the parasites except the Zucoagaricus genus mycelium extract which reduced by 47% the number of bloodstream forms. Striatin A, striatin B and podoscyphic acid exhibited in vitro activity at 10, 5 and 100 μg/mL, respectively. One compound showed activity against bloodstream forms of T. cruzi , the sesquiterpenoid naematolin, lysing the parasites by 79%. BALB/c mice infected with L. amazonensis were treated 3 weeks post‐infection with striatin A and striatin B by subcutaneous route for 15 days at 10 mg/kg daily. The reference drug, N‐methylglucamine antimonate, administered by subcutaneous injections at 28 mg Sbv/kg/day for 15 days reduced the parasite burden by 71.2% ( p <0.05). Subcutaneous administration of straitin A at 10 mg/kg produced a weak decrease of the parasite burdens in the footpad by 17.6%. The treatment with striatin B had no effect and showed higher toxicity than striatin A. © 1997 John Wiley & Sons, Ltd.